{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'Worsening of disease-related symptoms (e.g., worsening dyspnea, increasing', 'pain/increasing requirement for narcotic analgesics).', 'Decline in performance status of > 1 level on ECOG scale.', '10 SAFETY EVALUATION', '10.1 ADVERSE EVENTS', '10.1.1 Definition', 'An adverse event or adverse experience (AE) is any untoward medical occurrence associated with', 'the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be ANY', 'unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease', 'temporally associated with the use of a medicinal (investigational) product, whether or not', 'considered related to the medicinal (investigational) product (attribution of \"unrelated\\', \\'unlikely\\',', \"'possible', 'probable', or 'definite')\", 'An AE is considered \"unexpected\" if it is not listed in the investigator brochure or is not listed at', 'the specificity or severity that has been observed; or if an investigator brochure is not required or', 'available, is not consistent with the risk information described in the general investigational plan', 'in other study-related documents.', '10.1.1.1 Diagnosis Versus Signs and Symptoms', 'If known, a diagnosis should be recorded on the CRF rather than individual signs and symptoms', '(e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated', 'transaminases). However, if a constellation of signs and/or symptoms cannot be clinically', 'characterized as a single diagnosis or syndrome at the time of reporting, each individual event', 'should be recorded as an AE or SAE on the CRF. If a diagnosis is subsequently established, it', 'should be reported as follow-up information.', '10.1.1.2 Adverse Events Occurring Secondary to Other Events', 'In general, AEs occurring secondary to other events (e.g., cascade events or clinical sequelae)', 'should be identified by their primary cause. For example, if severe diarrhea is known to have', 'resulted in dehydration, it is sufficient to record only diarrhea as an AE or SAE on the CRF.', 'However, medically significant AEs occurring secondary to an initiating event that are separated', 'in time should be recorded as independent events on the CRF. For example, if a severe', 'gastrointestinal hemorrhage leads to renal failure, both events should be recorded separately on', 'the CRF.', '10.1.1.3 Abnormal Laboratory Values', 'Only clinically significant laboratory abnormalities that require active management will be', 'recorded as AEs or SAEs on the CRF (e.g., abnormalities that require study drug dose', 'modification, discontinuation of study treatment, more frequent follow-up assessments, further', 'diagnostic investigation, etc.).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 37 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'If the clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline', 'phosphatase and bilirubin 5 x the upper limit of normal associated with cholecystitis), only the', 'diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse Event CRF.', 'If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the', 'abnormality itself should be recorded as an AE or SAE on the CRF. If the laboratory abnormality', 'can be characterized by a precise clinical term, the clinical term should be recorded as the AE or', 'SAE. For example, an elevated serum potassium level of 7 mEq/L should be recorded as', '\"hyperkalemia\".', 'Observations of the same clinically significant laboratory abnormality from visit to visit should', 'not be repeatedly recorded as AEs or SAEs on the CRF, unless their severity, seriousness, or', 'etiology changes.', '10.1.1.4 Preexisting Medical Conditions (Baseline Conditions)', 'A preexisting medical condition should be recorded as an AE or SAE only if the frequency,', 'severity, or character of the condition worsens during the study. When recording such events on', 'an Adverse Event CRF, it is important to convey the concept that the preexisting condition has', 'changed by including applicable descriptors (e.g., \"more frequent headaches\").', '10.1.2 Grading and Relationship to Drug', 'The descriptions and grading scales found in the CTEP Version 4 of the NCI Common', 'Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting. CTEP', 'Version 4 of the CTCAE is identified and located at:', 'ttp://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm.', 'AEs not covered by specific terminology listed should be reported with common medical', 'terminology and graded according to definitions provided in the CTCAE Version 4.', 'The relationship of event to study drug will be documented by the Investigator as follows:', \"Unrelated: The event is clearly related to other factors such as the participant's clinical state,\", 'other therapeutic interventions or concomitant drugs administered to the participant.', 'Unlikely: The event is doubtfully related to investigational agent(s). The event was most likely', \"related to other factors such as the participant's clinical state, other therapeutic interventions,\", 'or concomitant drugs.', 'Possible: The event follows a reasonable temporal sequence from the time of drug', \"administration, but could have been produced by other factors such as the participant's clinical\", 'state, other therapeutic interventions or concomitant drugs.', 'Probable: The event follows a reasonable temporal sequence from the time of drug', 'administration, and follows a known response pattern to the study drug. The event cannot be', \"reasonably explained by other factors such as the participant's clinical state, therapeutic\", 'interventions or concomitant drugs.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 38 of 64']\n\n###\n\n", "completion": "END"}